Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2020-12-18 16:15:18
Reporting Period:
Accepted Time:
2020-12-18 16:15:18
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1624658 Allena Pharmaceuticals Inc. ALNA () 4
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1389500 Md Louis Brenner C/o Allena Pharmaceuticals, Inc.
One Newton Executive Park, Suite 202
Newton MA 02462
President And Ceo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2020-12-17 103,116 $1.36 144,816 No 4 S Direct
Common Stock Acquisiton 2020-12-17 247,932 $0.00 247,932 No 4 M Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 M Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2020-12-17 247,932 $0.00 247,932 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 M Direct
  1. The sale reported on this Form 4 was effected by the Reporting Person and represents shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units
  2. Each restricted stock unit represents a contingent right to receive one share of common stock.
  3. On December 2, 2019, the Reporting Person was granted 123,966 restricted stock units, vesting in two equal installments on June 2, 2020 and December 2, 2020 (the "December 2019 Grant"). On May 28, 2020, the reporting person was granted an additional 123,966 restricted stock units (the "May 2020 Grant") and the December 2019 Grant was amended to vest in full, together with the May 2020 Grant, on December 2, 2020. 247,932 shares of common stock were distributed to the Reporting Person on December 17, 2020 following the vesting of the restricted stock units from the December 2019 Grant and the May 2020 Grant